Elevated Cystatin C Levels Predict Pre-Diabetes

Study is a 6-year follow-up of Western New York Health Study

MONDAY, July 30 (HealthDay News) -- Elevated levels of cystatin C are associated with a threefold higher risk of developing pre-diabetes, according to a nested case-control study published in the July issue of Diabetes Care.

Richard P. Donahue, Ph.D., and colleagues re-examined 1,455 men and women (39-79 years) from the Western New York Health Study who did not have type 2 diabetes or cardiovascular disease. Of these, 91 progressed from a fasting glucose level of less than 100 mg/dl at baseline (1996-2001) to between 101 and 125 mg/dl at the follow-up examination (2002-2004), which was defined as incident pre-diabetes in the study.

After matching the patients with 273 controls and adjusting for confounding factors, an elevated baseline concentration of cystatin C was found to be a "highly statistically significant" predictor of pre-diabetes (odds ratio, 3.28). The association with cystatin C was found to be independent of other variables, including obesity, baseline glucose, serum creatinine, and albumin-to-creatinine ratio.

"Cystatin C has been shown recently to predict incident coronary heart disease events," the authors concluded, "suggesting that the renal/heart disease connection may share common mechanisms. Our findings provide an important new avenue for future research, suggesting that mild renal impairment may occur early in the natural history of diabetes."

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing